Safety and Efficacy of Asundexian in Preventing Adverse Cardiovascular Outcomes Following Acute MI
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Circulation
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes Following Acute Myocardial Infarction
Circulation 2022 Aug 27;[EPub Ahead of Print], SV Rao, B Kirsch, DL Bhatt, A Budaj, R Coppolecchia, J Eikelboom, SK James, WS Jones, B Merkely, L Keller, RS Hermanides, G Campo, JL Ferreiro, T Shibasaki, H Mundl, JH AlexanderFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.